Mobile Site ›

Autoantibody Profiles Of Myasthenia Gravis, Thymoma, and Lambert-Eaton Myasthenic Syndrome

An Update


Receive notification when new Hot Topics are published:

Reasons to Discontinue Testing for AChR Blocking Antibody

Slide 15

May 2012

Previously a test that measured acetylcholine receptor blocking antibodies was offered, but this was to be found of minimal clinical utility because it measures acetylcholine receptor blocking antibody only. The test is positive in 66% of patients with myasthenia gravis with moderate or severe generalized weakness. The test is never positive when acetylcholine receptor binding and modulating antibody tests are negative. The actual test for modulating antibody detects blocking antibody in addition. The blocking antibody test was not additionally informative for thymoma risk. Taking all of the factors into account, it is felt at this point that it is not cost effective.

Reasons to Discontinue Testing


Jump to section: